BioCentury
ARTICLE | Clinical News

RP101: Phase I/II data

February 14, 2005 8:00 AM UTC

Data from an open-label, German Phase I/II trial in 13 patients showed that RP101 plus gemcitabine/cisplatin increased the 50% probability of survival by about an average of 15 months compared to a hi...